Macia, S, Aladid, RL, Tovar, R, Garmendia, L, Lillo, CP, Fossati, M, Romero, ML, Selles, AN, Castellano, D, Gonzalezbilla, E, Maroto-Rey, JP, Piulats, JM, Lista, AGD, Parente, P. Explainable machine learning for continuous transcriptomic modeling of metastatic risk in prostate cancer (MET-score).. JOURNAL OF CLINICAL ONCOLOGY. 2026; 44(16_SUPPL)DOI:10.1200/JCO.2026.44.16_suppl.5129. PMID:. IF:41.900(Q1/1D).

Alvarez, RMA, Hindi, N, Carrasco-Garcia, I, Sanfilippo, R, Sebio, A, Redondo, A, Alvarez, A, Morosi, C, Romagosa, C, Artigas, V, Casares, CM, Asencio, JM, Guzmán-Gómez, L, González-Lopez, J, Belinchon, B, Sangalli, C, Gutierrez, A, Jurado, JC, Broto, JM, Gronchi, A. Trabectedin with concomitant radiotherapy in resectable retroperitoneal L-sarcoma: A multicenter, prospective, phase I/II trial-A collaborative study by the Spanish (GEIS), Italian (ISG), and French (FSG) groups.. JOURNAL OF CLINICAL ONCOLOGY. 2026; 44(16_SUPPL)DOI:10.1200/JCO.2026.44.16_suppl.11507. PMID:. IF:41.900(Q1/1D).

Moura, DS, Mondaza-Hernandez, JL, Shirikova, A, Romero-Gonzalez, P, Carrera, M, Rodriguez, C, Martínez-Trufero, J, Sebio, A, Jurado, JC, Valverde, C, Beveridge, RD, Carrasco-Garcia, I, Gonzalez-Billalabeitia, E, Fernandez-Jara, J, Lopez-Jimenez, C, Hindi, N, Gutierrez, A, Broto, JM. Prognostic significance of HMGB1 expression as a biomarker of immunogenic cell death in patients with leiomyosarcoma and undifferentiated pleomorphic sarcoma treated with chemo-immuno-based regimens. JOURNAL OF CLINICAL ONCOLOGY. 2026; 44(16_SUPPL)DOI:10.1200/JCO.2026.44.16_suppl.e23526. PMID:. IF:41.900(Q1/1D).

Gelderblom, H, Wang, V, Doherty, M, Sebio, A, Stacchiotti, S, Wilky, BA, Blay, JY, Brohl, AS, Morales, CMV, Reichardt, P, Martin-Broto, J, Davis, EJ, De Haan, JJ, O'Neill, B, Babcock, E, Garcia, J, Senne, L, Shepard, D, Chawla, SP, Jones, RL. The tetravalent death receptor 5 (DR5) agonist ozekibart (INBRX-109) in conventional chondrosarcoma (CS): Secondary efficacy endpoints from the randomized, registrational, phase 2 ChonDRAgon study.. JOURNAL OF CLINICAL ONCOLOGY. 2026; 44(16_SUPPL)DOI:10.1200/JCO.2026.44.16_suppl.11504. PMID:. IF:41.900(Q1/1D).

Ferrer, L, Nadal, E, Dejean, T, Insa, A, Menu, P, Casal, J, Domine, M, Massuti, B, Majem, M, Martinez-Marti, A, Garcia-Campelo, R, Carpeño, JD, Cobo, M, Vivanco, GL, Morillo, ED, Bernabé, R, Vinolas, N, Barneto, I, Colin, T, Provencio, M. Cross-stage validation of a multimodal machine learning model to predict pathological complete response to neoadjuvant chemotherapy or chemoimmunotherapy in resectable stage III non-small cell lung cancer.. JOURNAL OF CLINICAL ONCOLOGY. 2026; 44(16_SUPPL)DOI:10.1200/JCO.2026.44.16_suppl.8022. PMID:. IF:41.900(Q1/1D).

Pacheco-Barcia, V, Obispo, B, Tomas, E, de Torres, CS, Quintanar, T, Paez, D, Leon-Mateos, L, Cancio, H, Cortegoso, A, Anido, U, Quilez, A, Tarazona, N, Jimenez-Labaig, P, Sanchez-Martinez, DA, Goni, AS, Fernandez-Montes, A, Felip, E, Rodriguez, C, Elez, E. Interventional strategies to address burnout in young medical oncologists: results from the Resilience-Spanish Society of Medical Oncology (SEOM) Study and a university hospital experience in Spain. Clinical & Translational Oncology. 2026; 28(6)DOI:10.1007/s12094-025-04171-x. PMID:41436708. IF:2.500(Q3/6D).

González-Lopez, J, Sebio, A, Broto, JM, Hindi, N, Villarejo-Campos, P, Jimenez, M, Díaz-Beveridge, R, Castellanos, JFO, Andajar, RL, Alvarez, RMA, Asencio, JM, Serrano, C, Conde, NR, Castro-Boix, S, Krauel, L, Colom, H, García, JAT, Lopera, E, Huguet, A, Campos, AP. First-in-human phase I study of CEB-01, a biodegradable SN-38-releasing membrane, to prevent local recurrence after resection of retroperitoneal sarcoma: Updated results. JOURNAL OF CLINICAL ONCOLOGY. 2026; 44(16_SUPPL)DOI:10.1200/JCO.2026.44.16_suppl.e23559. PMID:. IF:41.900(Q1/1D).

Garrido, P, Villanueva, N, Bernabé, R, Campelo, RG, Sala, MA, Bote-de Cabo, H, Molla, MAI, Alvarez, R, Cruz, P, Majem, M, Santos, MAM, Cordero, MG, Rodriguez, JMO, Alvarez, RMA, Alvarez-Abril, B, Gutiérrez-Sainz, L, Gutiérrez, V, Munoz-Unceta, N, Felip, E, Isla, D. Sex-specific trends and outcomes in small cell lung cancer (SCLC) in Spain: Insights from the CLARISSE study (2019-2024).. JOURNAL OF CLINICAL ONCOLOGY. 2026; 44(16_SUPPL)DOI:10.1200/JCO.2026.44.16_suppl.8092. PMID:. IF:41.900(Q1/1D).

Broto, JM, Terés, R, Marquina, G, Perez-Fidalgo, JA, Lopez-Jimenez, C, Alonso-Romero, JL, Redondo, A, Gutierrez, A, Casado, A, Sebio, A, Ledesma, P, Merino-Garcia, JA, Mayordomo, E, Moura, DS, Hindi, N. Phase I trial of LB-100 plus doxorubicin as first-line of advanced soft tissue sarcomas: A Spanish Sarcoma Group (GEIS) study.. JOURNAL OF CLINICAL ONCOLOGY. 2026; 44(16_SUPPL)DOI:10.1200/JCO.2026.44.16_suppl.11572. PMID:. IF:41.900(Q1/1D).

Mondaza-Hernandez, JL, Moura, DS, Redondo, A, Sebio, A, Beveridge, RD, Martínez-Trufero, J, Romero-Gonzalez, P, Shirikova, A, Rodriguez, C, Carrera, M, Lopez-Jimenez, C, Hindi, N, Broto, JM. Plasma ISG15 as predictor of outcome from antiangiogenic therapy in solitary fibrous tumor: Analysis from the GEIS-69 trial. JOURNAL OF CLINICAL ONCOLOGY. 2026; 44(16_SUPPL)DOI:10.1200/JCO.2026.44.16_suppl.e23520. PMID:. IF:41.900(Q1/1D).

Cerezuela-Fuentes, P, Piñero-Madrona, A, Muñoz-Couselo, E, Manzano, JL, Berciano-Guerrero, MA, Majem, M, Espinosa, E, Soria, A, de Miguel, PA, Castaño, AG, Crespo, G, Sanz, LG, de la Rosa, CA, Fernández-Morales, LA, Puértolas, T, Rodríguez, JF, de la Borbolla, MR, Bellido, L, Castro, RL, Pérez, VN, Arroyo, FRG, Guzmán, JCV, Balea, BC, Hernández, B, Algarra, SM, Márquez-Rodas, I. Title: Characterization of Melanoma of Unknown Primary in the Era of Immunotherapy and Targeted Therapy in Spain: Results from the Prospective Real World Study GEM 1801. Clinical & Translational Oncology. 2026; 28(6)DOI:10.1007/s12094-025-04164-w. PMID:41420791. IF:2.500(Q3/6D).

Montañá, JR, Roselló, S, Paez, D, Safont, MJ, Vidal, J, Gravalos, C, Polo, E, Jimenez-Fonseca, P, Calle, SG, Paredes, BG, Beltran, M, Gonzalo-Ruiz, J, Rosales, C, Palmer, HG, Garcia, DL, Nuciforo, P, Vivancos-Prellezo, A, Tabernero, J, Elez, E. Bevacizumab plus encorafenib-cetuximab in BRAF V600E mutated metastatic colorectal cancer (mCRC): A phase II study with a safety lead-in cohort (the BRAVE trial).. JOURNAL OF CLINICAL ONCOLOGY. 2026; 44(16_SUPPL)DOI:10.1200/JCO.2026.44.16_suppl.TPS3681. PMID:. IF:41.900(Q1/1D).

Martin-Broto, J, Martinez-Trufero, J, Diaz-Beveridge, R, Gutierrez, A, Carrasco, I, Lopez-Jimenez, C, Sebio, A, González-Billalabeitia, E, Ramos, R, Romagosa, C, Merino, J, Fernandez-Jara, J, Hernandez-Vargas, L, Garmendia, MD, Cruz-Jurado, J, Valverde, C, Mondaza-Hernandez, JL, Carrera, MA, Ledesma, P, Hindi, N, Moura, DS. Safety and Efficacy of Epirubicin, Ifosfamide, and Nivolumab as First-Line Treatment for Patients with Undifferentiated Pleomorphic Sarcoma. CLINICAL CANCER RESEARCH. 2026; 32(11)DOI:10.1158/1078-0432.CCR-26-0032. PMID:41817407. IF:10.200(Q1/1D).

Aviles, P, Ribeiro, ML, Guillén, MJ, Martinez-Diez, M, Muñoz-Alonso, MJ, Santamaria-Nuñez, G, Torralba, D, Alamo, P, Gallardo, A, Oliva, MA, Mangues, R, Diaz, JF, Cuevas, C. PM534, a Novel Colchicine Site Tubulin Inhibitor with Broad-Spectrum and Resistance-Overcoming Antitumor Activity. MOLECULAR CANCER THERAPEUTICS. 2026; 25(6)DOI:10.1158/1535-7163.MCT-25-0559. PMID:41481906. IF:5.500(Q1/2D).

Bartoletti, M, Del Turco, ER, Bussini, L, Paul, M, Sabik, EF, Castagna, A, Ripa, M, Gomes, MZR, Di Bella, S, Malosso, M, Lopez, AB, Franceschini, E, Bandera, A, Barbieri, V, Oliva, A, Munoz, P, Mularoni, A, Seminari, E, Morelli, P, Tascini, C, Papadimitriou-Olivgeris, M, Coppola, N, Cristini, F, Russo, A, Bassetti, M, Travi, G, Contreras, JL, Varisco, B, Viale, P, Cento, V, Gaibani, P, Bavaro, DF, Giannella, M. Monotherapy vs. combination therapy for Enterococcus faecalis bacteraemia: a target trial emulation. CLINICAL MICROBIOLOGY AND INFECTION. 2026; 32(6)DOI:10.1016/j.cmi.2026.03.018. PMID:41850617. IF:8.500(Q1/1D).

Hornuss, D, Mathé, P, Giesen, R, Escolà-Vergé, L, Isler, B, Bartoletti, M, Lamy, B, Wagner, D, Kern, WV, Rieg, S. Quality indicators for clinical infectious diseases consultations?results from a hybrid Delphi-nominal group approach and scenario study. CLINICAL MICROBIOLOGY AND INFECTION. 2026; 32(6)DOI:10.1016/j.cmi.2026.03.006. PMID:41831716. IF:8.500(Q1/1D).

Lázaro, AR, Mediano, O, Cano-Pumarega, I, Ruiz-Martínez, C, Cristeto, M, Agudo, MA, Lázaro, J, Bozalongo, LP, Vicente, P, Egea, C, Pía, C, Mora, JU, Sánchez, LP, Romero, S, Barrio, PR, Anon, MM, Barbe, F, Dolores, M, Peláez, CM, Podzamczer, I, Fortuna, AM, González, M, de Teran, TD, Dalmases, M, García, J, Alonso-Fernández, A, Bravo, MD, Cabriada-Nuño, V, Gajate, AU, Sanmartí, NG, Farrés, MM, Aguirre, MC, Salord, N, Fontanilles, E, Faus, CC, Pinedo, AR, Navas, IH, Gutiérrez, ML, Arcos, BA, Chinarro, BJ, Avalos, E, Carpi, MM, Perez, RC, Boukichou, N, De La Torre, MS. Long-term Symptom, Psychological, and Functional Outcomes in Patients With Obstructive Sleep Apnea and Excessive Daytime Sleepiness Treated With Cpap: 24-month Results From the Hypnosa Cohort. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE. 2026; 212DOI:10.1093/ajrccm/aamag286.318. PMID:. IF:19.400(Q1/1D).

Escolà-Gil, JC, Rotllan, N, Llorente-Cortes, V. Special issue: Lipid metabolic alterations in cancer: Pathogenic mechanisms, therapies and common pathophysiology with cardiovascular disease. SEMINARS IN CANCER BIOLOGY. 2026; 123DOI:10.1016/j.semcancer.2026.06.001. PMID:42248269. IF:15.700(Q1/1D).

Jiménez-Garcia, L, Pérez-Montero, A, Herranz, S, Luque, A, Tarín, C, Castillo, D, Lopez-Vilaro, L, Mariñas-Pardo, L, McCarthy, C, Acebo, P, Hortelano, S. p19ARF deficiency disrupts lung and lipid homeostasis resembling the human alveolar proteinosis. AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY. 2026; 74(6)DOI:10.1093/ajrcmb/aanag003. PMID:41738246. IF:5.300(Q1/2D).

Honey, MIJ, Hok-A-Hin, YS, Thijssen, EH, Cousins, KAQ, van der Weijden, B, In't Veld, L, Stoops, E, de Boer, SCM, Duits, FH, de Houwer, JFH, Morrema, THJ, Alcolea, D, Illán-Gala, I, Fortea, J, Lleó, A, Boxer, AL, Irwin, DJ, Lee, EB, Shaw, L, McMillan, CT, Wolk, DA, Hoozemans, JJM, van der Flier, WM, van der Ende, E, Seelaar, H, Verberk, IMW, Gan, L, Pijnenburg, Y, Teunissen, CE. An acetylated Tau-174 CSF biomarker discriminates between TDP-43 and tau pathology in patients with frontotemporal lobar degeneration. NATURE MEDICINE. 2026; 32(6)DOI:10.1038/s41591-026-04341-6. PMID:41986736. IF:50.000(Q1/1D).